Hi-Aspect has an experienced management team
and high quality Board.
Dr George Slim
Dr George Slim has worked with many life science companies to develop and commercialise their research and intellectual property. He formerly led a large team of biochemists at Industrial Research Limited and had a science management role in the former Ministry of Research, Science and Technology.
George has a PhD in chemistry from the University of Otago, which he followed by postdoctoral research at the University of Cambridge and the MRC Laboratory of Molecular Biology.
Dr Leonardo Negron
Dr Leonardo Negron is a senior research scientist and team leader at Callaghan Innovation. He has expertise in protein science and engineering, and has worked in the development of medical devices, and skin and wound care products. Leonardo has a degree in Pharmacy from St. John’s University (New York) and a PhD in chemistry from Massey University (Palmerston North). He has previously been employed by Purdue Pharma, Lundbeck Research, Roche Molecular Systems and Aroa Biosurgery (formerly Mesynthes) as a researcher and product developer.
Dr Manmeet Kaur
Manmeet completed her PhD in Biochemistry at the University of Canterbury and joined Hi-Aspect as the company’s first full-time employee in 2016. She has a broad range of expertise in protein chemistry, food biotechnology, bio-nanotechnology and bionanomaterials. She was awarded a MacDiarmid Institute Research Internship to start her work with Hi-Aspect.
Dr Laura Domigan
Dr Laura Domigan is a research fellow in the School of Biological Sciences at the University of Auckland. She has expertise in the development of protein biomaterials for nanotechnology and tissue engineering.
Laura has a PhD in biochemistry from the University of Canterbury (New Zealand), and completed post-doctoral studies in biomedical engineering at Tufts University (Massachusetts).
Elizabeth Hopkins is Director of Research and Innovation at Lincoln University, a board member of Innate Therapeutics and deputy chair of the Canterbury Polytechnic Institute of Technology. She is a specialist in scientific commercialisation, and pharmaceutical and biotechnology management and has held senior executive positions with several prominent biotechnology companies in New Zealand and overseas including Keratec, EnCoate and Pfizer in the UK.
Elizabeth was educated at Oxford Brookes University.
Her specialties include all aspects of IP commercialisation from initial investment in research right through to manufacturing and sales of final product.
Jennifer Anderson is an investment manager with Powerhouse. She has led the commercialisation and development of many nutraceutical and biotechnology products, and medical devices, alongside researchers in academic, institutional and private sectors.
Professor Juliet Gerrard
Juliet Gerrard is a professor in the School of Biological Sciences and the School of Chemical Sciences at the University of Auckland. Her research spans protein biosynthesis, interactions and the use of protein chemistry in the food industry.
Juliet was a co-director of the Biomolecular Interaction Centre, based at the University of Canterbury, is a Principal Investigator in the MacDiarmid and Riddet Institutes and an Associate Investigator in the Maurice Wilkins Centre. She is also a director of Plant & Food Research, Chair of the Marsden Fund Council and was made a Fellow of the Royal Society of New Zealand in 2012.
Juliet’s research has a broad base, cutting across biochemistry, chemistry, health, agricultural and food science and biomaterial design, including protein nanomaterials. The author of more than 125 publications, Juliet gained her DPhil in biological chemistry from Oxford University.